Kathryn Lang, MD of Guardant Health provides an overview of data presented at AACR 2020 that shows that the LUNAR-2 assay achieved 90% sensitivity and 94% specificity in detecting early-stage CRC.1 When restricting analysis of the controls to those who were negative for CRC by colonoscopy (n=74), the LUNAR-2 assay demonstrated improved specificity (99%) with no reduction in sensitivity. These results are consistent with previously reported data2 showing that the company’s multi-modal, cancer-specific circulating tumor DNA (ctDNA) technology increases test sensitivity to deliver clinically meaningful results.
Liquid Biopsy Highly Accurate in Detecting Early-Stage Colorectal Cancer Overview
